Experimental panic provocation in healthy man-a translational role in anti-panic drug development?

about

The Deakin/Graeff hypothesis: focus on serotonergic inhibition of panic.Blunted autonomic reactivity to pharmacological panic challenge under long-term escitalopram treatment in healthy men

P2860

Q27022602-AEC8A1B2-AD5B-44DC-A438-6A74BAA77C42 Q35224278-E53305DA-2D6B-40AC-9B16-12A0B7DA9AF9

P2860

Experimental panic provocation in healthy man-a translational role in anti-panic drug development?

Item

http://www.wikidata.org/entity/Q35686873

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Experimental panic provocation ...... n anti-panic drug development?

@ast

Experimental panic provocation ...... n anti-panic drug development?

@en

type

Item

label

Experimental panic provocation ...... n anti-panic drug development?

@ast

Experimental panic provocation ...... n anti-panic drug development?

@en

prefLabel

Experimental panic provocation ...... n anti-panic drug development?

@ast

Experimental panic provocation ...... n anti-panic drug development?

@en

P1476

Experimental panic provocation ...... n anti-panic drug development?

@en

P2093

Michael Kellner

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported

P2860

Translocator protein (18 kD) as target for anxiolytics without benzodiazepine-like side effects

Psychiatric symptom-provoking studies: an ethical appraisal.

Evaluation of the CCK-4 model as a challenge paradigm in a population of healthy volunteers within a proof-of-concept study.

Placebo-controlled trial of the CCK-B antagonist, CI-988, in panic disorder.

Dose ranging study of the effects of cholecystokinin in healthy volunteers

Effects of citalopram treatment on behavioural, cardiovascular and neuroendocrine response to cholecystokinin tetrapeptide challenge in patients with panic disorder

Vigabatrin decreases cholecystokinin-tetrapeptide (CCK-4) induced panic in healthy volunteers.

Effect of CI-988 on cholecystokinin tetrapeptide-induced panic symptoms in healthy volunteers.

The cholecystokinin-B receptor antagonist CI-988 failed to affect CCK-4 induced symptoms in panic disorder patients.

Controlled cross-over study in normal subjects of naloxone-preceding-lactate infusions; respiratory and subjective responses: relationship to endogenous opioid system, suffocation false alarm theory and childhood parental loss.

P304

485-493

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2011-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22275853

http://www.w3.org/2001/XMLSchema#string

P921

Chidenhi

peptide

heterocyclic compound

panic attack

panic disorder

P932

3263395

http://www.w3.org/2001/XMLSchema#string

Experimental panic provocation in healthy man-a translational role in anti-panic drug development?

about

P2860

P2860

Experimental panic provocation in healthy man-a translational role in anti-panic drug development?

description

name

type

label

prefLabel

P1433

P1476

P2093

P275

P2860

P304

P31

P433

P478

P577

P698

P921

P932

P1433

P1476

P2093

P275

P2860

P304

P31

P433

P478

P577

P698

P921

P932